HC Wainwright Reiterates “Buy” Rating for TG Therapeutics (TGTX)
TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Monday. They presently have a $33.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 309.94% from the stock’s current price.
Several other analysts also recently issued reports on TGTX. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and set a $28.00 target price on shares of TG Therapeutics in a research note on Tuesday, October 3rd. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, B. Riley started coverage on TG Therapeutics in a research note on Friday, December 1st. They set a “buy” rating and a $21.50 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $25.50.
Shares of TG Therapeutics (TGTX) opened at $8.05 on Monday. TG Therapeutics has a 12 month low of $4.10 and a 12 month high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. equities research analysts expect that TG Therapeutics will post -1.86 EPS for the current year.
Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its stake in TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares during the last quarter. Bank of America Corp DE increased its stake in TG Therapeutics by 11.0% in the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 1,395 shares during the last quarter. BB&T Securities LLC increased its stake in TG Therapeutics by 63.0% in the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after acquiring an additional 6,549 shares during the last quarter. First Mercantile Trust Co. increased its stake in TG Therapeutics by 199.7% in the 2nd quarter. First Mercantile Trust Co. now owns 19,179 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 12,779 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in TG Therapeutics by 40.2% in the 2nd quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 6,463 shares during the last quarter. 50.45% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-tg-therapeutics-tgtx/1760547.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.